Tracking tumor DNA to predict relapse after upper kidney cancer surgery
Treatments studied
Part of Cancer clinical trials.
This study checks tumor DNA found in blood and urine to see who is at higher risk of the cancer coming back after surgery. It may help doctors identify “minimal residual disease,” meaning tiny amounts of cancer that can remain after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed upper tract urothelial cancer that is stage T2 to T4 or has lymph node spread, but no distant metastasis
- You are age 18 or older and willing to sign informed consent
- After surgery, you received chemotherapy or immunotherapy within about 12 weeks
- You can have at least two post-surgery liquid biopsy tests (blood/urine) at two time points (T1 and T2)
- Your health status is generally good (ECOG 0 to 2) and you can follow the study visits
- You do not have more than one primary cancer, and you do not have a history of bladder cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well patients do when they have kidney-sparing treatment (instead of complete kidney removal) for upper tract urothelial carcinoma. It helps doctors understand which patients can safely avoid losing their kidney.
This study uses a urine test to detect small amounts of cancer DNA (microscopic residual disease) after treatment, to see if it can catch a recurrence earlier than standard scans or cystoscopy. It includes four groups of people with different types and stages of urothelial cancer (in the kidney, ureter, or bladder) to see how well the test works for each group.
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
This trial checks if a DNA blood test can help decide who needs extra chemo after bladder or upper urinary tract cancer surgery. It tests whether watching for cancer DNA in the blood can match patients to the right treatment.
This Phase 2 trial studies a HER2-targeted medicine (RC48-ADC) plus another drug (JS001) to help prevent cancer from coming back after surgery for upper urinary tract urothelial cancer. It may be an option if your tumor has higher HER2 levels and you have no spread to distant organs.
This trial is for people with upper tract urothelial cancer who have already had surgery and chemotherapy (cisplatin-based). It tests whether continuing with a drug called avelumab (an immunotherapy) can help prevent the cancer from coming back.
Hear when a new Muscle Invasive Upper Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.